The fragment-based drug discovery market is projected to grow at an annualized rate of ~10%, till 2030
Roots Analysis has done a detailed study on Fragment-based Drug Discovery Market:Library and Service Providers, 2020-2030, covering key aspects of the industry’s evolution andidentifying potential future growth opportunities.
To order this 170+ pagereport, which features 55+ figures and 80+ tables, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html
Key Market Insights
§ Over 85 firms areinvolved in providing fragment-based drug discovery-related services; of these,around 40 players claim to offer both libraries and technologies
§ Industry stakeholdersoffer either customized fragment libraries or proprietary screeningtechnologies, a select few claim to provide both; however, the expertiserelated to fragment optimization is still limited in this domain
§ Majority ofstakeholders in the competitive market landscape are small / mid-sized firms,offering a variety of services to cater to the needs of a diverse clientele,featuring industry and non-industry players
§ Stakeholders areactively expanding their capabilities in order to enhance their respectivefragment-based drug discovery service portfolios and thereby, maintain acompetitive edge in this upcoming industry
§ The rising interest in this field is reflected in the number ofpartnerships inked in the recent past, involving both international andindigenous stakeholders, and focused on drug discovery for diverse range ofindications
§ Considering the prevalenttrend of drug discovery and approval, we are led to believe that thefragment-based approach has the potential to enable significant time and costsavings
§ The market is expected to witness growth at a CAGR of ~10%; theanticipated opportunity is likely to be distributed across various types ofscreening techniques, services and geographies
For more information, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVESUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overviewof Drug Development
3.3. DrugDiscovery Process
3.3.1. TargetIdentification
3.3.2. TargetValidation
3.3.3. HitGeneration
3.3.4. Hit-to-Lead
3.3.5. LeadOptimization
1.4. High-ThroughputScreening (HTS) and its Limitations
3.5. Fragment-basedDrug Discovery (FBDD)
PressRelease: Variation 2 (Format 3)
3.5.1. FBDD Strategies
3.5.2. ScreeningTechniques Used in FBDD
3.6. ChallengesRelated to FBDD
3.7. FuturePerspectives
4. CURRENTMARKET LANDSCAPE
4.1. ChapterOverview
4.2. Fragment-basedDrug Discovery: List of Library and Service Providers
4.2.1. Analysis byYear of Establishment of Company
4.2.2. Analysis byCompany Size and Geographical Location
4.2.3. LeadingLibrary and Service Providers: Analysis by Number of Products
4.2.4. Analysis byGeography
4.2.5. Analysis byType of Service Offered
4.2.6. Analysis byType of Technique Used
4.2.7. Analysis byOther Services Offered
4.2.8. Analysis byEnd User
4.3. Fragment-basedDrug Discovery: List of Libraries and Technologies
4.3.1. Analysis byType of Product
5. COMPANYPROFILES: FRAGMENT-BASED DRUG DISCOVERY LIBRARY AND SERVICE
PROVIDERS
5.1. ChapterOverview
5.2. 2bind
5.2.1. Recent Developmentsand Future Outlook
5.3. CharlesRiver Laboratories
5.3.1. RecentDevelopments and Future Outlook
5.4. ChemAxon
5.4.1. RecentDevelopments and Future Outlook
5.5. ComInnex
5.5.1. RecentDevelopments and Future Outlook
5.6. CreativeBiolabs
5.6.1. RecentDevelopments and Future Outlook
5.7. CreativeBiostructure
5.8. CRELUX
5.8.1. RecentDevelopments and Future Outlook
5.9. Domainex
5.9.1. RecentDevelopments and Future Outlook
5.10. Evotec
5.10.1. RecentDevelopments and Future Outlook
5.11. Red GleadDiscovery
5.12. SARomicsBiostructures
5.13. ShanghaiChemPartner
5.13.1. RecentDevelopments and Future Outlook
PressRelease: Variation 2 (Format 3)
5.14. SygnatureDiscovery
5.14.1. Recent Developmentsand Future Outlook
5.15. VernalisResearch
5.15.1. RecentDevelopments and Future Outlook
6. PARTNERSHIPSAND COLLABORATIONS
6.1. ChapterOverview
6.2. PartnershipModels
6.3. Fragment-basedDrug Discovery Services Market: List of Partnerships and Collaborations
6.3.1. Analysis byYear of Partnership
6.3.2. Analysis byType of Partnership
6.3.3. Analysis byYear of Partnership and Type of Partner
6.3.4. Most ActivePlayers: Analysis by Number of Partnerships
6.3.5. RegionalAnalysis
6.3.6. Intercontinentaland Intracontinental Agreements
7. KEY ACQUISITION TARGETS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Scoring Criteria and Key Assumptions
7.4. PotentialStrategic Acquisition Targets in North America
7.5. PotentialStrategic Acquisition Targets in Europe
7.6. PotentialStrategic Acquisition Targets in Asia-Pacific
7.7. ConcludingRemarks
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. ChapterOverview
8.2. Methodology
8.3. Key Parameters
8.4. CompetitivenessAnalysis: Fragment-based Drug Discovery Library and Service Providers
8.4.1. Fragment-basedDrug Discovery Library and Service Providers based in North America
8.4.2. Fragment-basedDrug Discovery Library and Service Providers based in Europe
8.4.3. Fragment-basedDrug Discovery Library and Service Providers based in Asia-Pacific
9.1. Chapter Overview
9.2. Key Assumptions and Parameters
9.3. Methodology
9.4. OverallCost Saving Potential Associated with FBDD, 2020-2030
9.5. ConcludingRemarks
10. MARKETFORECAST AND OPPORTUNITY ANALYSIS
10.1. ChapterOverview
10.2. KeyAssumptions and Forecast Methodology
10.3. GlobalFragment-based Drug Discovery Market, 2020-2030
10.4. GlobalFragment-based Drug Discovery Market: Distribution by Type of Technique, 2020and
2030
10.4.1. Fragment-basedDrug Discovery Market for X-ray Crystallography, 2020-2030
10.4.2. Fragment-basedDrug Discovery Market for Nuclear Magnetic Resonance, 2020-2030
10.4.3. Fragment-basedDrug Discovery Market for Surface Plasmon Resonance, 2020-2030
10.4.4. Fragment-basedDrug Discovery Market for Other Screening Techniques, 2020-2030
10.5. GlobalFragment-based Drug Discovery Market: Distribution by Type of Service, 2020 and2030
10.5.1. Fragment-basedDrug Discovery Market for Library Screening, 2020-2030
Press Release: Variation 2 (Format 3)
10.5.2. Fragment-basedDrug Discovery Market for Fragment Screening, 2020-2030
10.5.3. Fragment-basedDrug Discovery Market for Fragment Optimization, 2020-2030
10.6. GlobalFragment-based Drug Discovery Market: Distribution by End User, 2020 and 2030
10.6.1. Fragment-basedDrug Discovery Market for Industry Players, 2020-2030
10.6.2. Fragment-basedDrug Discovery Market for Non-industry Players, 2020-2030
10.7. GlobalFragment-based Drug Discovery Market: Distribution by Geography, 2020 and 2030
10.7.1. Fragment-basedDrug Discovery Market in the US, 2020-2030
10.7.2. Fragment-basedDrug Discovery Market in Canada, 2020-2030
10.7.3. Fragment-basedDrug Discovery Market in the UK, 2020-2030
10.7.4. Fragment-basedDrug Discovery Market in France, 2020-2030
10.7.5. Fragment-basedDrug Discovery Market in Germany, 2020-2030
10.7.6. Fragment-basedDrug Discovery Market in Spain, 2020-2030
10.7.7. Fragment-basedDrug Discovery Market in Italy, 2020-2030
10.7.8. Fragment-basedDrug Discovery Market in Rest of Europe, 2020-2030
10.7.9. Fragment-basedDrug Discovery Market in China, 2020-2030
10.7.10. Fragment-based Drug Discovery Market in Japan,2020-2030
10.7.11. Fragment-based Drug Discovery Market in India,2020-2030
10.7.12. Fragment-based Drug Discovery Market in Rest ofAsia-Pacific and Rest of the World, 2020-
2030
11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Edelris
11.2.1. CompanySnapshot
11.2.2. InterviewTranscript: Jean-Yves Ortholand, Co-founder & Chief Executive Officer
11.3. SARomicsBiostructures
11.3.1. CompanySnapshot
11.3.2. InterviewTranscript: Björn Walse, Chief Executive Officer
12. CONCLUDINGREMARKS
13. APPENDIX1: TABULATED DATA
14. APPENDIX2: LIST OF COMPANIES AND ORGANIZATIONS
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
